remove_red_eye 477 Views
#Dermatology #Hematology #Oncology #Pathology and Lab Medicine #Pharmacist
In patients taking adjuvant pembrolizumab for stage III melanoma, immune-related adverse events (irAE) are associated with longer recurrence-free survival (RFS), a secondary analysis of trial data suggests.
As reported in JAMA Oncology, 1,011 patients were included. RFS was longer with pembrolizumab compared with placebo (hazard ratio, 0.56). The incidence of irAEs was 37.4% in the pembrolizumab arm and 9% in the placebo arm, with a similar incidence in men and women. Occurrence of an irAE was associated with a longer RFS for those on pembrolizumab (HR, 0.61) in both men and women. However, the association was not significant for those on placebo.